Table 1.
Selected clinical trials for ovarian cancer with tumor-associated carbohydrate antigen-targeting agents or immune cell therapy. EAGLE bispecific fusion protein was developed on the basis of enzyme‒antibody glyco-ligand editing, ADC antibody–drug conjugates, ADCC antibody-dependent cell-mediated cytotoxicity, and CAR-T chimeric antigen receptor T cells
| Type | Modality | Target | Tumor type | Agent / Biological | Function | Phase | Clinical trial number |
|---|---|---|---|---|---|---|---|
| Antibody | ADCC | Globo-H | advanced or metastatic solid tumors | OBI-888 | mAb targeting Globo-H | I/II | NCT03573544 |
| ADCC | MUC1-Tn | advanced solid tumors | Gatipotuzumab | mAb targeting truncated O-glycans on MUC1 | I | NCT03360734 | |
| ADCC | Lewis Y | Ovarian Cancer | 3S193 | mAb targeting/blocking Lewis Y | II | NCT00617773 NCT01137071 | |
| ADCC | MUC1-Tn | Ovarian Cancer | PankoMab-GEX | mAb targeting truncated O-glycans on MUC1 | II | NCT01899599 | |
| ADC | Globo-H | advanced solid tumors | OBI-999 | Globo-H mAb and monomethyl auristatin E | I/II | NCT04084366 | |
| ADC | Lewis Y | advanced solid tumors | LMB-9 | LMB-9 immunotoxin IV | I | NCT00005858 | |
| ADC | Lewis Y | Ovarian Cancer | SGN15 | SGN-15 combined with gemcitabine | II | NCT00051584 | |
| ADC | STn | advanced solid tumors | SGN STNV | mAb targeting STn coupled to monomethyl auristatin E | I | NCT04665921 | |
| ADC | TA-MUC1 | advanced solid tumors | DS-3939a | mAb targeting truncated O-glycans on MUC1 | I | NCT05875168 | |
| EAGLE | Sialoglycans | advanced solid tumors | E-602 | NEU2-Fc for desialylating immunosuppressive sialoglycans | I | NCT05259696 | |
| Vaccine | Vaccine | Globo-H-GM2-sTn-TF-Tn | Ovarian Cancer | MabVax/MSKCC | Globo-H-GM2-sTn-TF-Tn-KLH conjugate | I | NCT01248273 |
| Anti-idiotype | ACA125 | Ovarian Cancer | Abagovomab | Functionally imitates the tumor associated antigen CA-125 | II /III | NCT00058435/NCT00418574 | |
| CAR T | CAR T | STn | Ovarian Cancer | TAG72-CAR T | TAG72-Targeting Chimeric Antigen Receptor T Cells | I | NCT05225363 |
| CAR T | MUC1-Tn | TnMUC1-Positive Advanced Cancers | CAR T-TnMUC1 | MUC1-Tn Targeting Chimeric Antigen Receptor T Cells | I | NCT04025216 | |
| CAR T | Lewis Y | advanced solid tumors | LeY CAR T cells | Lewis Y Targeting Chimeric Antigen Receptor T Cells | I | NCT03851146 | |
| Diagnostic | Diagnostic | 500 glycoproteoforms | Ovarian Cancer | liquid biopsy—specific glycoproteomic signatures | I | NCT03837327 |